文献速递类风湿关节炎

特立帕肽对类风湿关节炎关节侵蚀的影响:一项随机对照试验

Effects of Teriparatide on Joint Erosions in Rheumatoid Arthritis: A Randomized Controlled Trial.
PubMed 文献 · Arthritis Rheumatol · 2017-07-14

该随机对照试验纳入24例接受TNF抑制剂治疗且疾病活动度受控的侵蚀性RA合并骨量减少患者,比较特立帕肽治疗1年与等待对照对关节侵蚀体积的影响。结果显示特立帕肽组52周侵蚀体积中位变化为-0.4 mm3,与对照组+9.1 mm3无显著差异(P=0.28),提示特立帕肽未显著减少侵蚀体积。

要点

  • 特立帕肽治疗1年未显著减少RA手或腕关节侵蚀体积。
  • 特立帕肽组股骨颈和腰椎骨密度改善。
  • 研究样本量小(24例),需谨慎解读阴性结果。

核心结论

  • 特立帕肽治疗1年未显著减少接受TNF抑制剂且疾病活动度受控的 established RA 患者手或腕关节侵蚀体积。

研究设计与样本

  • 随机对照试验,纳入24例侵蚀性RA、骨量减少且TNF抑制剂治疗至少3个月疾病活动度受控的患者,半数接受特立帕肽治疗1年,其余为等待对照。
  • 受试者和主要风湿科医生未设盲,但所有结局采用盲法评估。

主要发现

  • 52周时特立帕肽组侵蚀体积中位变化为-0.4 mm3(IQR -34.5, 29.6),对照组为+9.1 mm3(IQR -29.6, 26.4),组间差异无统计学意义(P=0.28)。
  • 桡骨、尺骨或掌指关节的侵蚀体积变化均未观察到显著差异。
  • 特立帕肽组股骨颈和腰椎骨密度改善。

关键数值与推荐

  • 主要结局为CT评估的6个解剖部位侵蚀体积变化,采用双尾检验,P<0.05为显著。

临床怎么用

  • 对于接受TNF抑制剂且疾病活动度受控的 established RA 合并骨量减少患者,特立帕肽不宜以减少关节侵蚀为主要目的使用。
  • 特立帕肽可能改善骨密度,但需结合个体情况权衡使用。

局限性

  • 样本量小(24例),可能不足以检测侵蚀体积的微小变化。
  • 受试者和主要风湿科医生未设盲,但结局评估采用盲法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Articular erosions correlate with disability in rheumatoid arthritis (RA). Biologic agents reduce erosion progression in RA, but erosion healing occurs infrequently. This study was undertaken to assess the effects of the anabolic agent teriparatide on joint erosion volume in RA patients treated with a tumor necrosis factor inhibitor (TNFi). METHODS: We conducted a randomized controlled trial in 24 patients with erosive RA, osteopenia, and disease activity controlled by TNFi treatment for at least 3 months. Half were randomized to receive teriparatide for 1 year and the others constituted a wait-list control group. Subjects and primary rheumatologists were not blinded with regard to treatment assignment, but all outcomes were assessed in a blinded manner. The primary outcome measure was change in erosion volume determined by computed tomography at 6 anatomic sites. Significance within each hand and anatomic site was based on a 2-tailed test, with P values less than 0.05 considered significant. RESULTS: Baseline characteristics of the treatment groups were well balanced. After 52 weeks, the median change in erosion volume in the teriparatide group was -0.4 mm3 (interquartile range [IQR] -34.5, 29.6) and did not differ significantly from that in controls (median change +9.1 mm3 [IQR -29.6, 26.4]) (P = 0.28). No significant difference in change in erosion volume was noted at the radius, ulna, or metacarpophalangeal joints. Bone mineral density improved at the femoral neck and lumbar spine in the teriparatide group. CONCLUSION: Our findings indicate that teriparatide treatment for 1 year does not significantly reduce erosion volume in the hands or wrists of patients with established RA with disease activity controlled by TNFi treatment.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Solomon DH, Kay J, Duryea J, et al. Effects of Teriparatide on Joint Erosions in Rheumatoid Arthritis: A Randomized Controlled Trial. Arthritis Rheumatol. 2017. PMID: 28544807. doi:10.1002/art.40156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。